In patients with triple-negative breast cancer, high expression levels of NUP98, identified by immunohistochemistry, have been proposed to be a predictor of response to anthracycline-based chemotherapy and poor overall survival [36]. Here, NUP98 is linked to triple-negative breast carcinoma.